208 related articles for article (PubMed ID: 10956304)
1. Antiarrhythmic drugs: from mechanisms to clinical practice.
Roden DM
Heart; 2000 Sep; 84(3):339-46. PubMed ID: 10956304
[No Abstract] [Full Text] [Related]
2. [Ion channels and arrhythmias].
Borchard U; Hafner D
Z Kardiol; 2000; 89 Suppl 3():6-12. PubMed ID: 10810780
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on the current treatment of cardiac arrhythmias.
Bigger JT
Am J Cardiol; 1984 Aug; 54(4):2B-7B. PubMed ID: 6147081
[TBL] [Abstract][Full Text] [Related]
4. Drugs for cardiac arrhythmias.
Treat Guidel Med Lett; 2007 Jun; 5(58):51-8. PubMed ID: 17505408
[No Abstract] [Full Text] [Related]
5. Antiarrhythmic drug therapy (Part 1). Benefits and hazards.
Podrid PJ
Chest; 1985 Sep; 88(3):452-60. PubMed ID: 2863091
[No Abstract] [Full Text] [Related]
6. Antiarrhythmic drugs: electrophysiological basis of their clinical usage.
Weng JT; Smith DE; Moulder PV
Ann Thorac Surg; 1986 Jan; 41(1):106-12. PubMed ID: 2417568
[TBL] [Abstract][Full Text] [Related]
7. Drugs for cardiac arrhythmias.
Med Lett Drugs Ther; 1989 Apr; 31(790):35-40. PubMed ID: 2565011
[No Abstract] [Full Text] [Related]
8. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis.
Chay TR
J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110
[TBL] [Abstract][Full Text] [Related]
9. [Current classification of anti-arrhythmia agents].
Weirich J; Wenzel W
Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
[TBL] [Abstract][Full Text] [Related]
10. Risks and benefits of antiarrhythmic therapy.
Roden DM
N Engl J Med; 1994 Sep; 331(12):785-91. PubMed ID: 8065408
[No Abstract] [Full Text] [Related]
11. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
Skanes AC; Morton BC; Green MS; Tang AS
Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
[TBL] [Abstract][Full Text] [Related]
12. Drugs for cardiac arrhythmias.
Med Lett Drugs Ther; 1991 Jun; 33(846):55-60. PubMed ID: 1674978
[No Abstract] [Full Text] [Related]
13. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
Bollmann A; Husser D; Cannom DS
Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
[TBL] [Abstract][Full Text] [Related]
14. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates.
Roden DM
Am J Cardiol; 1996 Aug; 78(4A):12-6. PubMed ID: 8780324
[TBL] [Abstract][Full Text] [Related]
15. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
Singh BN; Wadhani N
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
[TBL] [Abstract][Full Text] [Related]
16. [Calcium antagonists: sites of action, pharmacologic effect profile and clinical use. 2: Pharmacologic effects, indications and side effects of calcium antagonists].
Bluth R; Langnickel R
Z Arztl Fortbild (Jena); 1986; 80(6):237-40. PubMed ID: 2424182
[No Abstract] [Full Text] [Related]
17. Adverse cardiovascular drug interactions.
Opie LH
Curr Probl Cardiol; 2000 Sep; 25(9):621-76. PubMed ID: 11043147
[No Abstract] [Full Text] [Related]
18. Medical management of atrial fibrillation: future directions.
Page RL
Heart Rhythm; 2007 Mar; 4(3 Suppl):S91-4. PubMed ID: 17336894
[TBL] [Abstract][Full Text] [Related]
19. Antiarrhythmic agents: current status and perspectives.
Mátyus P; Varró A; Papp JG; Wamhoff H; Varga I; Virág L
Med Res Rev; 1997 Sep; 17(5):427-51. PubMed ID: 9276860
[No Abstract] [Full Text] [Related]
20. Sodium channel blockers in the treatment of ventricular arrhythmias: different effects in the normal, ischaemic or failing heart?
Haverkamp W; Hindricks G; Fechtrup C; Borggrefe M; Breithardt G
Eur Heart J; 1991 Dec; 12 Suppl F():10-7. PubMed ID: 1666550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
